SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms

Janeri Fröberg, Joshua Gillard, Ria Philipsen, Kjerstin Lanke, Joyce Rust, Diana van Tuijl, Karina Teelen, Teun Bousema, Elles Simonetti, Christa E van der Gaast-de Jongh, Mariska Bos, Frank J van Kuppeveld, Berend-Jan Bosch, Marrigje Nabuurs-Franssen, Nannet van der Geest-Blankert, Charlotte van Daal, Martijn A Huynen, Marien I de Jonge, Dimitri A Diavatopoulos

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Although serological studies have shown that antibodies against SARS-CoV-2 play an important role in protection against (re)infection, the dynamics of mucosal antibodies during primary infection and their potential impact on viral load and the resolution of disease symptoms remain unclear. During the first pandemic wave, we assessed the longitudinal nasal antibody response in index cases with mild COVID-19 and their household contacts. Nasal and serum antibody responses were analysed for up to nine months. Higher nasal receptor binding domain and spike protein-specific antibody levels at study inclusion were associated with lower viral load. Older age was correlated with more frequent COVID-19 related symptoms. Receptor binding domain and spike protein-specific mucosal antibodies were associated with the resolution of systemic, but not respiratory symptoms. Finally, receptor binding domain and spike protein-specific mucosal antibodies remained elevated up to nine months after symptom onset.

Original languageEnglish
Article number5621
Pages (from-to)1-11
JournalNature Communications
Volume12
Issue number1
DOIs
Publication statusPublished - Dec 2021

Bibliographical note

Funding Information:
We would like to thank all MuCo study participants for their willingness to participate and their support for the study. In addition, we thank M. Boonstra, M. Blok, D. van der Giessen, E. Lenssen, E. Reuvers, M. Roek and E. Wijnhoven for assisting with performing the first home visit, H. Lyoo from Utrecht University for experimental assistance, J. Heijnen, M. Dautzenberg and A. Voss for recruiting participants from the occupational health and safety officers at Rijnstate and CWZ hospitals, and the respective medical microbiology departments involved in PCR testing of hospital employees. This study was funded by the Laboratory of Medical Immunology, Radboud University Medical Center.

Publisher Copyright:
© 2021, The Author(s).

Fingerprint

Dive into the research topics of 'SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms'. Together they form a unique fingerprint.

Cite this